Núñez Gil, Iván JavierFeltes, GiselaViana Llamas, María C.Raposeiras Roubín, SergioRomero, RodolfoAlfonso Rodríguez, EmilioUribarri, AitorSantoro, FrancescoBecerra Muñoz, Víctor ManuelPérez Villacastín, JuliánEt al.2024-01-302024-01-302023Núñez-Gil, I. J., Feltes, G., Viana-Llamas, M. C., Raposeiras-Roubin, S., Romero, R., Alfonso-Rodríguez, E., Uribarri, A., Santoro, F., Becerra-Muñoz, V., Pepe, M., Castro-Mejía, A. F., Signes-Costa, J., Gonzalez, A., Marín, F., Lopez-País, J., Cerrato, E., Vázquez-Cancela, O., Espejo-Paeres, C., López Masjuan, Á., … HOPE COVID-19 investigators (2023). Post-COVID-19 Symptoms and Heart Disease: Incidence, Prognostic Factors, Outcomes and Vaccination: Results from a Multi-Center International Prospective Registry (HOPE 2). Journal of Clinical Medicine, 12(2), 706. https://doi.org/10.3390/jcm120207062077-0383http://hdl.handle.net/11268/12621Background: Heart disease is linked to worse acute outcomes after coronavirus disease 2019 (COVID-19), although long-term outcomes and prognostic factor data are lacking. We aim to characterize the outcomes and the impact of underlying heart diseases after surviving COVID-19 hospitalization. Methods: We conducted an analysis of the prospective registry HOPE-2 (Health Outcome Predictive Evaluation for COVID-19-2, NCT04778020). We selected patients discharged alive and considered the primary end-point all-cause mortality during follow-up. As secondary main end-points, we included any readmission or any post-COVID-19 symptom. Clinical features and follow-up events are compared between those with and without cardiovascular disease. Factors with p < 0.05 in the univariate analysis were entered into the multivariate analysis to determine independent prognostic factors. Results: HOPE-2 closed on 31 December 2021, with 9299 patients hospitalized with COVID-19, and 1805 died during this acute phase. Finally, 7014 patients with heart disease data were included in the present analysis, from 56 centers in 8 countries. Heart disease (+) patients were older (73 vs. 58 years old), more frequently male (63 vs. 56%), had more comorbidities than their counterparts, and suffered more frequently from post-COVID-19 complications and higher mortality (OR (heart disease): 2.63, 95% CI: 1.81-3.84). Vaccination was found to be an independent protector factor (HR (all-cause death): 0.09; 95% CI: 0.04-0.19). Conclusions: After surviving the acute phase, patients with underlying heart disease continue to present a more complex clinical profile and worse outcomes including increased mortality. The COVID-19 vaccine could benefit survival in patients with heart disease during follow-up.engAttribution-NonCommercial-NoDerivatives 4.0 Internacionalhttp://creativecommons.org/licenses/by-nc-nd/4.0/Infecciones por CoronavirusPronósticoMortalidadjournal article10.3390/jcm12020706open accessSistema cardiovascularVirus